Siegbert Rossol

Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Cost-Effectiveness and Budget Impact Analyses of Selective Internal Radiation Therapy versus Atezolizumab Plus Bevacizumab from a German Statutory Health Insurance Perspective.

Cost-Effectiveness and Budget Impact Analyses of Selective Internal Radiation Therapy versus Atezolizumab Plus Bevacizumab from a German Statutory Health Insurance Perspective.

Journal: ClinicoEconomics and outcomes research : CEOR

Published: March 06, 2024

Lifestyle interventions for patients with non-alcoholic steato-hepatitis-Design, rationale and protocol of the study "target group-specific optimisation of lifestyle interventions for behavior change in non-alcoholic steato-hepatitis (OPTI-NASH)".

Lifestyle interventions for patients with non-alcoholic steato-hepatitis-Design, rationale and protocol of the study "target group-specific optimisation of lifestyle interventions for behavior change in non-alcoholic steato-hepatitis (OPTI-NASH)".

Journal: PloS one

Published: June 23, 2023

Prevalence of metabolic syndrome : Analysis based on routine statutory health insurance data

Prevalence of metabolic syndrome : Analysis based on routine statutory health insurance data

Journal: Innere Medizin (Heidelberg, Germany)

Published: March 24, 2023

Is there a place for sigmoidoscopy in colorectal cancer screening? A systematic review and critical appraisal of cost-effectiveness models.

Is there a place for sigmoidoscopy in colorectal cancer screening? A systematic review and critical appraisal of cost-effectiveness models.

Journal: PloS one

Published: March 13, 2023

Intersectoral management of patients with abnormal liver enzymes and non-alcoholic fatty liver disease (NAFLD)

Intersectoral management of patients with abnormal liver enzymes and non-alcoholic fatty liver disease (NAFLD)

Journal: Zeitschrift fur Gastroenterologie

Published: February 15, 2023

Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R).

Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R).

Journal: Zeitschrift fur Gastroenterologie

Published: July 15, 2022

Frequency of diagnosed non-alcololic fatty liver disease (NAFLD) in the German population - An analysis based on health insurance data

Frequency of diagnosed non-alcololic fatty liver disease (NAFLD) in the German population - An analysis based on health insurance data

Journal: Zeitschrift fur Gastroenterologie

Published: March 23, 2021

Non-Invasive Reliable Methods to Objectify the Positive Influence of Hepatitis C Virus Treatment on Liver Stiffness.

Non-Invasive Reliable Methods to Objectify the Positive Influence of Hepatitis C Virus Treatment on Liver Stiffness.

Journal: Gastroenterology research

Published: November 30, 2020

Acute exacerbation of reactivated chronic hepatitis-b after stopping antiviral medication followed by loss of HBsAg

Acute exacerbation of reactivated chronic hepatitis-b after stopping antiviral medication followed by loss of HBsAg

Journal: Deutsche medizinische Wochenschrift (1946)

Published: April 16, 2020

Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.

Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.

Journal: BMC infectious diseases

Published: November 16, 2018

Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry.

Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry.

Journal: European journal of gastroenterology & hepatology

Published: October 17, 2018

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.

Journal: PloS one

Published: September 05, 2016

Showing 1-12 of 22

Last Updated: 09/26/2026